Lytix Biopharma ASA: Grant of share options to management and key personnel

Oslo, Norway - 3 September 2026 - Lytix Biopharma ASA (the "Company") announces
that the Board of Directors has approved the grant of 1,076,600 share options
under the Company's long-term incentive program.

The Board considers the grants an important part of the Company's strategy to
attract and retain key personnel with the experience and capabilities required
to support Lytix's continued development and strategic priorities.

Key terms of the grants
o	Each option gives the holder the right to acquire one share in the Company at
an exercise price of NOK 8.30, corresponding to the closing price of the
Company's shares on Euronext Growth Oslo on 2 September 2026.
o	No consideration is payable for the grant of the options. The applicable
exercise price must be paid upon exercise. 
o	A total of 999,700 options are subject to a 36-month linear vesting schedule
commencing in September 2026. The options will vest in equal monthly instalments
over the 36-month period, subject to the options holder's continued employment
or engagement with the Company.  
o	A total of 76,900 options are subject to the Company's standard four-year
vesting schedule. Of these options, 25% will vest 12 months after the date of
grant, while the remaining 75% will vest in equal monthly instalments over the
following 36 months, subject to the option holder's continued employment or
engagement with the Company. 
o	All options expire five years after the date of grant.

Allocation of the options
The following primary insider has been granted options:
o	Timothy Herpin, Chief Business Officer, 384,500 options

In addition, 692,100 options have been granted to new members of the Company's
key personnel who are not primary insiders.

Please refer to the notification form appended hereto for further information
regarding the option grant to the primary insider of the Company.

For further information, please contact:
Gjest Breistein, CFO
E-mail: gjest.breistein@lytixbiopharma.com

This information is subject to disclosure under section 5-12 of the Norwegian
Securities Trading Act and Article 19 of the Market Abuse Regulation.

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as monotherapy and in combination
therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.

For more information, visit www.lytixbiopharma.com.
er the ticker LYTIX.\
\
For more information\, visit www.lytixbiopharma.com.\